TriSalus Life Sciences (TLSI) to Release Earnings on Thursday

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

TriSalus Life Sciences Stock Performance

NASDAQ:TLSI traded up $0.26 during trading hours on Friday, reaching $5.64. The stock had a trading volume of 83,747 shares, compared to its average volume of 42,690. The stock has a 50 day simple moving average of $5.33 and a 200 day simple moving average of $4.71. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The stock has a market cap of $171.98 million, a P/E ratio of -2.27 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of analysts have issued reports on TLSI shares. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 target price for the company. Roth Mkm reissued a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Lake Street Capital started coverage on TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a "buy" rating and a $10.00 target price for the company. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $11.56.

Remove Ads

Insider Transactions at TriSalus Life Sciences

In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 4,826 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.42 per share, with a total value of $26,156.92. Following the transaction, the chief executive officer now owns 429,503 shares of the company's stock, valued at $2,327,906.26. The trade was a 1.14 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sean Murphy acquired 15,000 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was acquired at an average cost of $5.31 per share, for a total transaction of $79,650.00. Following the completion of the transaction, the insider now directly owns 182,732 shares in the company, valued at $970,306.92. This represents a 8.94 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 54,856 shares of company stock worth $294,608. Company insiders own 32.80% of the company's stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.